Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sertraline Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg in Fed Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 28, 2010
Lead Product(s) : Sertraline Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sertraline Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 28, 2010
Lead Product(s) : Sertraline Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka and Lundbeck Submit sNDA for FDA Review of Brexpiprazole and Sertraline Combination
Details : Rexulti (brexpiprazole) 5-HT2A receptor, is being evaluated in combination with sertraline in late-stage clinical trials with adult patients for the treatment of post-traumatic stress disorder.
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2024
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka and Lundbeck Submit sNDA for FDA Review of Brexpiprazole
Details : Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder.
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2024
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka and Lundbeck Announce FDA Acceptance for Brexpiprazole in PTSD Treatment
Details : Rexulti (brexpiprazole) is an partial agonist of serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2024
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sertraline Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Azrieli Foundation | Canadian Institutes of Health Research | Ontario Brain Institute | Holland Bloorview Kids Rehabilitation Hospital | McMaster University | Western University | Queen's University | University of Alberta | Alberta Health services | CHU
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2023
Lead Product(s) : Sertraline Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Azrieli Foundation | Canadian Institutes of Health Research | Ontario Brain Institute | Holland Bloorview Kids Rehabilitation Hospital | McMaster University | Western University | Queen's University | University of Alberta | Alberta Health services | CHU
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2023
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zent2U announces Completion of Bioequivalence Trials on Sertraline
Details : Sertraline hydrochloride potentiates serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT). It is indicated for the treatment of MDD, PTSD, PMDD, panic disorder, and social anxiety disorder.
Product Name : Sertraline Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 08, 2021
Lead Product(s) : Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride,Sertraline Hydrochloride,Venlafaxine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : It showed 60 milligrams of SLS-002 to be safe and well tolerated as a monotherapy or with an oral antidepressant.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 01, 2020
Lead Product(s) : Ketamine Hydrochloride,Sertraline Hydrochloride,Venlafaxine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un
Deal Size : Inapplicable
Deal Type : Inapplicable
Pragmatic Trial of Obsessive-compulsive Disorder
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 07, 2020
Lead Product(s) : Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un
Deal Size : Inapplicable
Deal Type : Inapplicable